On November 9, oncologists from more than 70 clinical research centers and experts from clinical trial institutions gathered in Guangzhou to participate in the multi-center, randomized controlled, open-label Phase III study of "Evaluating the efficacy and safety of YL201 for injection versus Topotecan hydrochloride for injection in patients with recurrent small cell lung cancer" organized by MediLink Therapeutics. Based on the availability of SCLC treatment in today's market and unmet clinical needs, in-depth exchanges and high-quality discussions were conducted regarding the design, preliminary clinical data, phase II study of YL201 and YL201-CN-302-01 research plan.

At the beginning of the conference, Dr.Tony Xue, founder and CEO of MediLink, and Professor Li Zhang, Leading PI investigator of YL201, delivered speeches and expressed sincere welcome and appreciation to researchers from all over the country.

Professor Li Zhang, chairman of the conference, commented that SCLC accounts for about 15% to 20% of the total population of lung cancer, and ORR and survival benefit of the current options for chemotherapy are limited. More effective treatment plans are urgently needed. YL201, as a novel B7H3-targeted antibody drug conjugate, has shown excellent efficacy and safety in early stage clinical trials, and is expected to become a new option in the market.

He called on the investigators to work together to complete the study on the basis of quality and quantity, and to accelerate the process of commercialization. Lastly, he wished a full success of the conference.

Prof. Hongyun Zhao, Vice Director of Clinical Research, Oncology Prevention and Treatment Center, Zhongshan University shared the results of the Phase II study of YL201. Based on the available efficacy and safety data of YL201, Phase III clinical trial will be conducted to evaluate the efficacy and safety of YL201 versus topotecan hydrochloride in recurrent SCLC patients who have failed initial platinum-based therapy to meet the clinical needs of patients with recurrent small cell lung cancer.

Experts had a heated discussion on the Phase III clinical study, clinical trial design, clinical trial operation and other issues of YL201, showing great expectations for the future efficacy and safety evaluation. They wish the project to achieve good clinical results in the near future, and ultimately bring more options to the vast number of cancer patients.

Dr.Tony Xue, Founder, CEO of MediLink stated that it was a great honor to have experts in the field of cancer from all over the world to witness the growth and progress of MediLink Therapeutics. The successful conference marks the formal and full launch of the first Phase III clinical trial study of YL201. We look forward to bringing YL201 to the market as soon as possible and benefiting more patients with the joint efforts of investigators.

In the future, we will continue to adhere to a scientific and rigorous attitude, adhere to continuous innovation, deepen the clinical research layout of each pipeline, and provide safe, efficacious and more accessible treatment options for cancer patients around the world.

Speech by Dr. Tony Xue, Chairman and CEO of MediLink

Speech by Professor Zhang Li, Chairman of the Conference

Dr. Steve Chin, CMO of MediLink, introduces the company and project situation

Professor Zhao Hongyun shares the research results of the YL201 Phase I/II clinical trials

Dr. Li Xufeng from MediLink introduces the Phase III plan for YL201